Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Bone Marrow Transplantation
|
November 27, 2007
Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI)
M Smetak, B Kimmel, J Birkmann, et al.
Bone Marrow Transplantation
|
September 18, 2003
What is CD4+CD56+ malignancy and how should it be treated?
P Reimer, T Rüdiger, D Kraemer, et al.
Journal of Oncology
|
March 20, 2010
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
S Gattenlöhner, B Etschmann, V Kunzmann, et al.
British Journal of Cancer
|
March 21, 2013
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades
A G Kerscher, T C Chua, M Gasser, et al.
European Journal of Radiology
|
April 20, 2023
Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113)
K V Guggenberger, T A Bley, S Held, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E G Chiorean, D D Von Hoff, M Reni, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Bone Marrow Transplantation
|
November 27, 2007
Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI)
M Smetak, B Kimmel, J Birkmann, et al.
Bone Marrow Transplantation
|
September 18, 2003
What is CD4+CD56+ malignancy and how should it be treated?
P Reimer, T Rüdiger, D Kraemer, et al.
Journal of Oncology
|
March 20, 2010
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
S Gattenlöhner, B Etschmann, V Kunzmann, et al.
British Journal of Cancer
|
March 21, 2013
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades
A G Kerscher, T C Chua, M Gasser, et al.
European Journal of Radiology
|
April 20, 2023
Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113)
K V Guggenberger, T A Bley, S Held, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E G Chiorean, D D Von Hoff, M Reni, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
Page
of 3